News | November 02, 2012

Mevion Medical Systems Continues Manufacturing Ramp up for Mevion S250 Proton Therapy System

A fifth proton accelerator enters manufacturing line at Mevion headquarters

Mevion S250 Proton Therapy

November 2, 2012 —  Mevion Medical Systems announced the delivery of its fifth TriNiobium Core proton accelerator, the powerful proton source that is at the center of the revolutionary Mevion S250 Proton Therapy System. This accelerator will be delivered early next year to First Coast Oncology in Jacksonville, Fla. All 2013 and early 2014 Mevion S250 deliveries are already in the manufacturing stage.

“The Mevion S250 has redefined the economics, availability, and the future direction of proton therapy, by bringing the management and operation of proton therapy to the level of modern radiation therapy,” said Scot Ackerman, medical director for First Coast Oncology. “Our Mission has been to provide the most advanced radiation treatment for our cancer patients, and the Mevion S250 will allow us to offer to our patients the full benefits of proton therapy.”

The Mevion S250 proton therapy system represents the latest innovation in proton therapy, providing the same precise, non-invasive treatment advantages and capabilities of larger proton therapy systems but with a significantly reduced footprint, improved reliability, high patient throughput, more advanced clinical systems and lower implementation and operational costs. Powered by a patented gantry-mounted TriNiobium Core accelerator, the Mevion S250 has a footprint only slightly larger than a conventional linear accelerator.

In addition to the construction at First Coast Oncology, the Mevion S250 is installed at Washington University, St. Louis, Mo., and is under installation at Robert Wood Johnson University Hospital, New Brunswick, N.J. and Oklahoma University. An additional site in Florida, MD Anderson Cancer Center in Orlando just broke ground in September 2012.

More than a dozen Mevion S250 proton therapy systems are slated to be installed in the United States including five NCI Designated Comprehensive Cancer Center, and six international projects. “The simple and modular design of the Mevion S250 supports a lean and fast manufacturing process. This is a first in proton therapy which traditionally has been limited by the enormous size and complexity of the device”, says Joseph K. Jachinowski, chief executive officer of Mevion Medical Systems. The Mevion S250 is the only proton therapy system designed and manufactured in the United States, and has recently received United States Food and Drug Administration (FDA) 510(k) clearance and CE certification enabling Mevion customers to treat patients.

For more information: www.Mevion.com

Related Content

Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy
Technology | Proton Therapy | January 04, 2018
Mevion Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Mevion S250i...
MEDraysintell Downgrades Proton Therapy Market Projection for 2030
News | Proton Therapy | January 02, 2018
MEDraysintell recently downgraded its projection for proton therapy rooms expected to be operational in 2030 from 1,200...
RaySearch Releases RayStation 7 Radiotherapy Treatment Planning System
Technology | Treatment Planning | December 19, 2017
RayStation 7, the latest release of RaySearch’s radiation therapy treatment planning system, adds new functionality and...
Baptist Hospital's Miami Cancer Institute Treats First Patient With Proteus Plus Proton Therapy
News | Proton Therapy | December 19, 2017
December 19, 2017 — IBA (Ion Beam Applications SA) announced that Miami Cancer Institute treated its first patients,
Mevion Achieves CE Mark for S250i Proton Therapy System
News | Proton Therapy | November 21, 2017
November 21, 2017 — Mevion Medical Systems announced the Mevion S250i...
RayStation Selected for New Tennessee Proton Therapy Center
News | Treatment Planning | November 20, 2017
November 20, 2017 — Provision Healthcare has selected RayStation for external beam planning at the new Provision Care
Proton therapy doesn’t get as near to the heart and other internal organs as X-ray therapy does. (Image courtesy of Provision Cares Proton Therapy Center.)

Proton therapy doesn’t get as near to the heart and other internal organs as X-ray therapy does. (Image courtesy of Provision Cares Proton Therapy Center.)

Feature | Proton Therapy | November 06, 2017 | By Larisa Brass, MPH
Thirty-three. Twenty-nine. Sixty-four. These are the ages of the breast cancer patients who have walked through the...
PTCOG-NA Studies Address Cost and Coverage Issues With Proton Therapy
News | Proton Therapy | November 01, 2017
Physicians from across the country gathered in Chicago last week to discuss the most recent advances in proton therapy...
Proton Therapy Lowers Treatment Side Effects in Pediatric Head and Neck Cancer Patients
News | Proton Therapy | November 01, 2017
Pediatric patients with head and neck cancer can be treated with proton beam therapy (PBT) instead of traditional...
Proton Therapy Shows Promising Clinical Benefits for Esophageal, Prostate and Breast Cancer
News | Proton Therapy | October 30, 2017
The National Association for Proton Therapy (NAPT) announced a number of clinical papers showing promising results were...
Overlay Init